| Dr Steven Charles Buck, DO | |
|
12697 E 51st St, Tulsa, OK 74146-6236 | |
| (918) 505-3200 | |
| (918) 505-3253 |
| Full Name | Dr Steven Charles Buck |
|---|---|
| Gender | Male |
| Speciality | Medical Oncology |
| Experience | 45 Years |
| Location | 12697 E 51st St, Tulsa, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154373835 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 2010 (Oklahoma) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Oklahoma Cancer Specialists And Research Institute, Llc | 0042513558 | 50 |
| Stillwater Medical Center Authority | 2365353794 | 131 |
News Archive
Taking medications as prescribed is challenging for many patients, and following doctors' orders regarding medication often varies over time and among different patients. The consequences of failing to follow the prescribed medication regimen range from mild to life-threatening, depending on the medication and the illness or condition being treated.
Gastric cancer, one of the leading causes of cancer-associated mortality worldwide, is renowned for its ability to disseminate throughout the peritoneal cavity.
Researchers at Guy's and St Thomas' NHS Foundation Trust have launched an innovative new trial which aims to improve the recovery of patients with serious heart conditions.
The U.S. Food and Drug Administration (FDA) has approved maraviroc, an antiretroviral drug for use in adult HIV patients. Maraviroc, sold under the trade name Selzentry, is the first in a new class of drugs designed to slow the advancement of HIV and received priority review by the FDA.
BioMarin Pharmaceutical Inc. today announced an update on the Phase I/II trial for BMN 110 or N-acetylgalactosamine 6-sulfatase (GALNS), intended for the treatment of the lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), or Morquio A Syndrome. Preliminary clinical data from the first 24 weeks of the study (12 weeks at 0.1mg/kg and 12 weeks at 1.0 mg/kg) have been evaluated, and BioMarin plans to announce top-line results for the full 36-week study after completion of dosing at 2.0 mg/kg in the second quarter of 2010.
› Verified 1 days ago
| Entity Name | Stillwater Medical Center Authority |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558377135 PECOS PAC ID: 2365353794 Enrollment ID: O20040525001304 |
News Archive
Taking medications as prescribed is challenging for many patients, and following doctors' orders regarding medication often varies over time and among different patients. The consequences of failing to follow the prescribed medication regimen range from mild to life-threatening, depending on the medication and the illness or condition being treated.
Gastric cancer, one of the leading causes of cancer-associated mortality worldwide, is renowned for its ability to disseminate throughout the peritoneal cavity.
Researchers at Guy's and St Thomas' NHS Foundation Trust have launched an innovative new trial which aims to improve the recovery of patients with serious heart conditions.
The U.S. Food and Drug Administration (FDA) has approved maraviroc, an antiretroviral drug for use in adult HIV patients. Maraviroc, sold under the trade name Selzentry, is the first in a new class of drugs designed to slow the advancement of HIV and received priority review by the FDA.
BioMarin Pharmaceutical Inc. today announced an update on the Phase I/II trial for BMN 110 or N-acetylgalactosamine 6-sulfatase (GALNS), intended for the treatment of the lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), or Morquio A Syndrome. Preliminary clinical data from the first 24 weeks of the study (12 weeks at 0.1mg/kg and 12 weeks at 1.0 mg/kg) have been evaluated, and BioMarin plans to announce top-line results for the full 36-week study after completion of dosing at 2.0 mg/kg in the second quarter of 2010.
› Verified 1 days ago
| Entity Name | Oklahoma Cancer Specialists And Research Institute, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104291236 PECOS PAC ID: 0042513558 Enrollment ID: O20160115001766 |
News Archive
Taking medications as prescribed is challenging for many patients, and following doctors' orders regarding medication often varies over time and among different patients. The consequences of failing to follow the prescribed medication regimen range from mild to life-threatening, depending on the medication and the illness or condition being treated.
Gastric cancer, one of the leading causes of cancer-associated mortality worldwide, is renowned for its ability to disseminate throughout the peritoneal cavity.
Researchers at Guy's and St Thomas' NHS Foundation Trust have launched an innovative new trial which aims to improve the recovery of patients with serious heart conditions.
The U.S. Food and Drug Administration (FDA) has approved maraviroc, an antiretroviral drug for use in adult HIV patients. Maraviroc, sold under the trade name Selzentry, is the first in a new class of drugs designed to slow the advancement of HIV and received priority review by the FDA.
BioMarin Pharmaceutical Inc. today announced an update on the Phase I/II trial for BMN 110 or N-acetylgalactosamine 6-sulfatase (GALNS), intended for the treatment of the lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), or Morquio A Syndrome. Preliminary clinical data from the first 24 weeks of the study (12 weeks at 0.1mg/kg and 12 weeks at 1.0 mg/kg) have been evaluated, and BioMarin plans to announce top-line results for the full 36-week study after completion of dosing at 2.0 mg/kg in the second quarter of 2010.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Steven Charles Buck, DO 12697 E 51st St, Tulsa, OK 74146-6236 Ph: (918) 505-3200 | Dr Steven Charles Buck, DO 12697 E 51st St, Tulsa, OK 74146-6236 Ph: (918) 505-3200 |
News Archive
Taking medications as prescribed is challenging for many patients, and following doctors' orders regarding medication often varies over time and among different patients. The consequences of failing to follow the prescribed medication regimen range from mild to life-threatening, depending on the medication and the illness or condition being treated.
Gastric cancer, one of the leading causes of cancer-associated mortality worldwide, is renowned for its ability to disseminate throughout the peritoneal cavity.
Researchers at Guy's and St Thomas' NHS Foundation Trust have launched an innovative new trial which aims to improve the recovery of patients with serious heart conditions.
The U.S. Food and Drug Administration (FDA) has approved maraviroc, an antiretroviral drug for use in adult HIV patients. Maraviroc, sold under the trade name Selzentry, is the first in a new class of drugs designed to slow the advancement of HIV and received priority review by the FDA.
BioMarin Pharmaceutical Inc. today announced an update on the Phase I/II trial for BMN 110 or N-acetylgalactosamine 6-sulfatase (GALNS), intended for the treatment of the lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), or Morquio A Syndrome. Preliminary clinical data from the first 24 weeks of the study (12 weeks at 0.1mg/kg and 12 weeks at 1.0 mg/kg) have been evaluated, and BioMarin plans to announce top-line results for the full 36-week study after completion of dosing at 2.0 mg/kg in the second quarter of 2010.
› Verified 1 days ago
Sarah Anne Shaw-dressler, D.O. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 6151 S Yale Ave Ste 100a, Tulsa, OK 74136 Phone: 918-494-8500 Fax: 918-307-5578 | |
Julia Margaret Kwon, DO Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 1705 E 19th St Ste 302, Tulsa, OK 74104 Phone: 918-748-7585 Fax: 918-748-7539 | |
Peter Madden, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 4502 E 41st St, Tulsa, OK 74135 Phone: 918-619-4400 | |
Thao Tran, D.O Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 4502 E. 41st Street, Tulsa, OK 74135 Phone: 918-619-4400 | |
Robert Peter Aran, D.O. Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 6160 S Yale Ave Ste 100, Tulsa, OK 74136 Phone: 918-497-3300 Fax: 918-497-3365 | |
Robert Dean Okada, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 6151 S Yale Ave, Ste 304, Tulsa, OK 74136 Phone: 918-494-5300 Fax: 918-494-5455 | |
Dr. Charles Wade Taylor, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 12697 E 51st St, Tulsa, OK 74146 Phone: 918-505-3200 Fax: 918-505-3253 |